MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue. NexoBrid has received regulatory approval in the European Union and by the U.S. Food and Drug Administration for use in adults with severe thermal burns. MediWound is also advancing EscharEx™, a topical therapy aimed at debriding chronic and hard-to-heal wounds, currently undergoing pivotal clinical trials to expand its therapeutic portfolio.
MediWound’s commercial reach spans North America, Europe and other international markets through a network of strategic distribution partners. In the United States, the company supports its sales efforts with a dedicated subsidiary and field-based clinical specialists, while in Europe it works with established distributors to ensure product availability and regulatory compliance. The company continues to explore additional indications and territories to broaden access to its enzymatic treatments.
Leadership at MediWound is spearheaded by Chief Executive Officer Dan Rosenwasser, who has guided the company’s strategic expansion and commercialization initiatives. Under his direction, MediWound has strengthened its manufacturing capabilities and fortified its clinical pipeline. The management team’s combined expertise in biotechnology, regulatory affairs and commercial operations underpins the company’s mission to deliver advanced wound care solutions to patients worldwide.
AI Generated. May Contain Errors.
